CD200 flow cytometric assessment and semiquantitative immunohistochemical staining distinguishes hairy cell leukemia from hairy cell leukemia-variant and other B-cell lymphoproliferative disorders

American Journal of Clinical Pathology

Volumn 140, Issue 4, 2013, Pages 536-543

  Pillai, Vinodh ^a   Pozdnyakova, Olga ^a   Charest, Karry ^a   Li, Betty ^a   Shahsafaei, Aliakbar ^a   Dorfman, David M ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Chronic lymphocytic leukemia; Hairy cell leukemia; Hairy cell leukemia variant; Mantle cell lymphoma

Indexed keywords

CD200 ANTIGEN;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; B CELL LYMPHOMA; CLINICAL ASSESSMENT; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; HAIRY CELL LEUKEMIA; HAIRY CELL LEUKEMIA VARIANT; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; MARGINAL ZONE LYMPHOMA; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; WALDENSTROEM MACROGLOBULINEMIA;

CHRONIC LYMPHOCYTIC LEUKEMIA; HAIRY CELL LEUKEMIA; HAIRY CELL LEUKEMIA-VARIANT; MANTLE CELL LYMPHOMA;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD; BONE MARROW CELLS; DIAGNOSIS, DIFFERENTIAL; FEMALE; FLOW CYTOMETRY; HUMANS; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; LEUKEMIA, HAIRY CELL; LYMPH NODES; LYMPHOMA, B-CELL, MARGINAL ZONE; MALE; MIDDLE AGED; TUMOR MARKERS, BIOLOGICAL; WALDENSTROM MACROGLOBULINEMIA;

EID: 84884942789     PISSN: 00029173     EISSN: 19437722     Source Type: Journal    
DOI: 10.1309/AJCPEBK31VQQNDDR     Document Type: Article

References (25)

1. McCaughan GW, Clark MJ, Barclay AN. Characterization of the human homolog of the rat MRC OX-2 membrane glycoprotein. Immunogenetics. 1987;25:329-335. (Pubitemid 17115653)
2. Wright GJ, Jones M, Puklavec MJ, et al. The unusual distribution of the neuronal/lymphoid cell surface CD200 (OX2) glycoprotein is conserved in humans. Immunology. 2001;102:173-179. (Pubitemid 32217509)
3. Hoek RM, Ruuls SR, Murphy CA, et al. Down-regulation of the macrophage lineage through interaction with OX-2 (CD200). Science. 2000;290:1768-1771. (Pubitemid 32004808)
4. Wright GJ, Cherwinski H, Foster-Cuevas M, et al. Characterization of the CD200 receptor family in mice and humans and their interactions with CD200. J Immunol. 2003;171:3034-3046. (Pubitemid 37093527)
5. Moreaux J, Hose D, Reme T, et al. CD200 is a new prognostic factor in multiple myeloma. Blood. 2006;108:4194-4197. (Pubitemid 44913292)
6. Tonks A, Hills R, White P, et al. CD200 as a prognostic factor in acute myeloid leukemia. Leukemia. 2007;21:566-568.
7. Moreaux J, Veyrune JL, Reme T, et al. CD200: a putative therapeutic target in cancer. Biochem Biophys Res Commun. 2008;366:117-122. (Pubitemid 350297222)
8. Petermann KB, Rozenberg GI, Zedek D, et al. CD200 is induced by ERK and is a potent therapeutic target in melanoma. J Clin Invest. 2007;117:3922-3929. (Pubitemid 350224101)
9. McWhirter JR, Kretz-Rommel A, Saven A, et al. Antibodies selected from combinatorial libraries block a tumor antigen that plays a key role in immunomodulation. Proc Natl Acad Sci U S A. 2006;103:1041-1046. (Pubitemid 43212218)
10. Kretz-Rommel A, Qin F, Dakappagari N, et al. CD200 expression on tumor cells suppresses antitumor immunity: new approaches to cancer immunotherapy. J Immunol. 2007;178:5595-5605. (Pubitemid 46674355)
11. Dorfman DM, Shahsafaei A. CD200 (OX-2 membrane glycoprotein) expression in B cell-derived neoplasms. Am J Clin Pathol. 2010;134:726-733.
12. Brunetti L, Di Noto R, Abate G, et al. CD200/OX2, a cell surface molecule with immune-regulatory function, is consistently expressed on hairy cell leukaemia neoplastic cells. Br J Haematol. 2009;145:665-678.
13. Dorfman DM, Brown JA, Shahsafaei A, et al. Programmed death-1 (PD-1) is a marker of germinal center-associated T cell and angioimmunoblastic T-cell lymphoma. Am J Surg Pathol. 2006;30:802-810. (Pubitemid 44264969)
14. Yu H, Shahsafaei A, Dorfman DM. Germinal center T helper cell markers PD-1 and CXCL13 are both expressed by neoplastic cells in angioimmunoblastic T-cell lymphoma. Am J Clin Pathol. 2009;131:33-41.
15. Dorfman DM, Shahsafaei A. CD200 (OX-2 membrane glycoprotein) is expressed by follicular T helper cells and in angioimmunoblastic T cell lymphoma. Am J Surg Pathol. 2011;35:76-83.
16. Swerdlow SH, Campo E, Harris NL, et al. WHO classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC; 2008.
17. Dorfman DM, Greisman HA, Shahsafaei A. Loss of expression of the WNT/-catenin-signaling pathway transcription factors lymphoid enhancer factor-1 (LEF-1) and T cell factor (TCF-1) in a subset of peripheral T cell lymphomas. Am J Pathol. 2003;162:1539-1544. (Pubitemid 36512836)
18. Dorfman DM, Hwang ES, Shahsafaei A, et al. T-bet, a T-cell-associated transcription factor, is expressed in a subset of B-cell lymphoproliferative disorders. Am J Clin Pathol. 2004;122:292-297. (Pubitemid 38971362)
19. Dorfman DM, Hwang ES, Shahsafaei A, et al. T-bet, a T-cell-associated transcription factor, is expressed in Hodgkin's lymphoma. Hum Pathol. 2005;36:10-15. (Pubitemid 40215628)
20. Kotsianidis I, Nakou E, Spanoudakis E, et al. The diagnostic value of CD1d expression in a large cohort of patients with B-cell chromic lymphoproliferative disorders. Am J Clin Pathol. 2011;136:400-408.
21. Dong HY, Weisberger J, Liu Z, et al. Immunophenotypic analysis of CD103+ B-lymphoproliferative disorders. Am J Clin Pathol. 2009;131:586-595.
22. Palumbo GA, Parrinello N, Fargione G, et al. CD200 expression may help in differential diagnosis between mantle cell lymphoma and B-cell chronic lymphocytic leukemia. Leuk Res. 2009;33:1212-1216.
23. Alapat D, Coviello-Malle J, Owens R, et al. Diagnostic usefulness and prognostic impact of CD200 expression in lymphoid malignancies and plasma cell myeloma. Am J Clin Pathol. 2012;137:93-100.
24. Kretz-Rommel A, Qin F, Dakappagari N, et al. Blockade of CD200 in the presence or absence of antibody effector function: implications of anti-CD200 therapy. J Immunol. 2008;180:699-705.
25. Kretz-Rommel A, Bowdish KS. Rationale for anti-CD200 immunotherapy in B-CLL and other hematologic malignancies: new concepts in blocking immune suppression. Expert Opin Biol Ther. 2008;8:5-15. (Pubitemid 351233719)